• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Orion Oyj (HLSE:ORNBV) Is Up 12.2% After Raising Its 2026 Guidance Has The Bull Case Changed?

    Simply Wall St·07/20/2026 03:25:27
    語音播報
    • In July 2026, Orion Oyj raised its full-year 2026 guidance, tightening net sales to €2,000 million–€2,100 million and operating profit to €650 million–€750 million, alongside reporting strong second-quarter and first-half results with higher sales, net income and earnings per share than a year earlier.
    • The company linked its improved outlook to robust collaboration income and commercial performance, while emphasizing that partnership-related payments remain difficult to forecast due to their dependence on R&D outcomes and contract milestones.
    • We’ll now examine how Orion’s upgraded 2026 guidance, particularly the higher floor for operating profit, interacts with its existing investment narrative.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    Orion Oyj Investment Narrative Recap

    To own Orion Oyj, you need to believe in its ability to turn a focused oncology and specialty portfolio, plus collaboration income, into resilient earnings while managing lumpier partner payments. The upgraded 2026 guidance, with a higher floor for operating profit, supports that thesis in the near term, but it also sharpens the key risk: how dependent short term performance is on inherently hard to predict milestone flows linked to R&D progress and contract timing.

    The recent co development and supply agreement for an intravenous nivolumab biosimilar in Europe feels particularly relevant here, because it reinforces how Orion’s guidance is tethered to collaboration driven revenue streams. The deal brings potential milestone and supply income on top of existing partnerships, and sits alongside oncology pipeline efforts, making it a meaningful part of the same catalyst set that underpins the higher 2026 profit range.

    Yet against the stronger outlook, investors should still be aware that Orion’s growing reliance on partnership and oncology milestones means...

    Read the full narrative on Orion Oyj (it's free!)

    Orion Oyj's narrative projects €2.6 billion revenue and €728.1 million earnings by 2029. This requires 9.6% yearly revenue growth and about a €198.7 million earnings increase from €529.4 million today.

    Uncover how Orion Oyj's forecasts yield a €74.33 fair value, a 4% downside to its current price.

    Exploring Other Perspectives

    HLSE:ORNBV 1-Year Stock Price Chart
    HLSE:ORNBV 1-Year Stock Price Chart

    Before this upgrade, the most optimistic analysts were already assuming about €2.5 billion of revenue and €635.7 million of earnings by 2029, which is far more bullish than consensus. If you worry about Orion’s dependence on Nubeqa royalties and oncology milestones, this guidance beat may either comfort you or make you question how much of that upside is already assumed, so it is worth comparing these different views side by side.

    Explore 5 other fair value estimates on Orion Oyj - why the stock might be worth over 2x more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Orion Oyj research is our analysis highlighting 4 key rewards that could impact your investment decision.
    • Our free Orion Oyj research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Orion Oyj's overall financial health at a glance.

    Looking For Alternative Opportunities?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.